Company: TVRD
Filing Date: 2025-05-13
Form Type: 8-K
Source: 0001104659-25-047856
Chunk: 4

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 8-K
Item: Item 4.01
Chunk 4
---
, 2025, Deloitte was engaged as the Company’s independent
registered public accounting firm. Deloitte served as the independent registered public accounting firm of Legacy Tvardi prior to the
consummation of the merger of Legacy Tvardi with the Delaware corporation formerly known as “ Cara Therapeutics, Inc.”

During the
Company’s fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through May 13, 2025, neither the Company
nor anyone acting on its behalf consulted with Deloitte regarding: (i) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the Company’s financial statements, and neither
a written report nor oral advice was provided to the Company that Deloitte concluded was an important factor considered by the Company
in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of
a “disagreement” within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 or a
“reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits.